Stock listing

Dusseldorf:AAJ0 Perspective Therapeutics, Inc. Aktie

German listing (Dusseldorf) of Perspective Therapeutics, Inc. · home listing NYSE American:CATX

Follow Perspective Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · AMEX:CATX

$0.754 USD -0.026 (-3.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, AMEX:CATX

Past year -64.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.741 – $0.791 USDNov 20, 2026
Volume
1.40M sharesNov 20, 2026
Market cap
$86.05M USDAt the close on Nov 20, 2026 · price × 114.2M shares outstanding
52-week range
$0.741 – $6.160 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.84M USDMedian day 1.67M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Perspective Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:CATX · Home$0.754 USD-0.026 (-3.4%)1,396,459$0.759$0.791$0.741$0.780Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:CATX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.754-0.026-3.4%$0.759$0.791$0.7411,396,459
$0.780-0.080-9.3%$0.864$0.871$0.7802,707,711
$0.860-0.064-6.9%$0.924$0.940$0.8102,818,682
$0.924-0.019-2.0%$0.940$1.020$0.9002,307,765
$0.943+0.101+12.0%$0.858$0.966$0.8543,184,384
$0.842+0.017+2.1%$0.890$0.900$0.8251,957,726
$0.825+0.039+4.9%$0.790$0.884$0.7878,790,866
$0.786-0.069-8.1%$0.856$0.906$0.7808,460,621
$0.856+0.016+1.9%$0.846$0.873$0.7902,932,760
$0.840+0.052+6.5%$0.787$0.907$0.7873,131,610
$0.788-0.082-9.4%$0.860$0.884$0.7813,832,859
$0.870-0.010-1.1%$0.897$0.964$0.8376,932,925
$0.880-0.160-15.4%$1.050$1.075$0.8768,404,710
$1.040-0.110-9.6%$1.150$1.185$1.0302,098,258
$1.150-0.020-1.7%$1.120$1.150$1.0902,309,335
$1.170-0.080-6.4%$1.250$1.275$1.1502,215,827
$1.250+0.060+5.0%$1.210$1.250$1.0654,593,438
$1.190-0.020-1.7%$1.200$1.260$1.0608,739,478
$1.210-0.400-24.8%$1.400$1.591$1.1159,622,962
$1.610-0.650-28.8%$2.400$2.400$1.5805,613,965
$2.260-0.040-1.7%$2.250$2.335$2.220967,762
$2.3000.0000.0%$2.320$2.365$2.2751,241,268
$2.300+0.110+5.0%$2.190$2.370$2.1901,812,751
$2.190+0.020+0.9%$2.200$2.249$2.1501,138,613
$2.170-0.170-7.3%$2.340$2.340$2.1501,669,659
$2.340+0.100+4.5%$2.270$2.370$2.2301,189,876
$2.240-0.030-1.3%$2.360$2.360$2.2101,394,498
$2.270-0.250-9.9%$2.500$2.520$2.2501,309,910
$2.520-0.140-5.3%$2.610$2.670$2.505640,582
$2.660-0.050-1.8%$2.710$2.755$2.6251,104,732
$2.710+0.250+10.2%$2.430$2.730$2.3703,255,036
$2.460+0.100+4.2%$2.370$2.510$2.3221,285,777
$2.360-0.210-8.2%$2.590$2.600$2.3002,702,852
$2.570-0.190-6.9%$2.750$2.820$2.4803,560,749
$2.760+0.040+1.5%$2.770$2.820$2.6852,622,136
$2.720-0.030-1.1%$2.710$2.775$2.6601,542,531
$2.750+0.130+5.0%$2.640$2.775$2.5501,670,313
$2.620+0.120+4.8%$2.520$2.620$2.4901,542,351
$2.500-0.020-0.8%$2.500$2.575$2.4601,504,853
$2.520+0.020+0.8%$2.500$2.525$2.4501,801,824
$2.500-0.120-4.6%$2.580$2.590$2.4401,698,409
$2.620-0.340-11.5%$2.890$2.920$2.5003,161,056
$2.960-0.010-0.3%$3.000$3.020$2.8145,145,236
$2.970+0.090+3.1%$2.940$3.030$2.8952,111,840
$2.8800.0000.0%$2.890$2.940$2.77011,636,161
$2.880+0.180+6.7%$2.760$2.920$2.7401,168,195
$2.700-0.030-1.1%$2.730$2.750$2.6201,582,357
$2.730-0.190-6.5%$2.880$2.890$2.6601,474,352
$2.920+0.110+3.9%$2.810$2.960$2.7902,024,407
$2.810+0.040+1.4%$2.770$2.825$2.6652,024,744
$2.770-0.220-7.4%$2.960$3.010$2.7501,582,652
$2.990-0.130-4.2%$3.070$3.108$2.9601,499,216
$3.120-0.010-0.3%$3.120$3.180$3.0201,061,381
$3.130+0.010+0.3%$3.070$3.180$3.0251,365,189
$3.120+0.020+0.6%$3.090$3.140$3.030931,703
$3.1000.0000.0%$3.100$3.235$3.025864,638
$3.100-0.060-1.9%$3.160$3.165$3.070705,838
$3.160+0.050+1.6%$3.110$3.180$3.080910,730
$3.110-0.070-2.2%$3.160$3.170$3.075913,335
$3.180+0.020+0.6%$3.150$3.240$3.100797,531
$3.160-0.130-4.0%$3.280$3.300$3.140799,217
$3.290+0.100+3.1%$3.220$3.325$3.200773,771
$3.190-0.110-3.3%$3.320$3.370$3.130678,656
$3.300+0.090+2.8%$3.250$3.440$3.2201,135,300
$3.210-0.270-7.8%$3.460$3.560$3.1801,180,700

Splits

1 split · AMEX:CATX · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
Dusseldorf:AAJ0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Perspective Therapeutics, Inc. news

Perspective Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 39 in all · newest Nov 9, 2026 · oldest 2025
Decks
41 decks · latest Nov 9, 2026

Where Perspective Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:CATX · Home listingNYSE AmericanUnited StatesUSD
gettex:AAJ0gettexGermanyEUR
BOATS:CATXBOATSUnited StatesUSD
LS Exchange:A40EDRLS ExchangeGermanyEUR
Lang & Schwarz:A40EDRLang & SchwarzGermanyEUR
Dusseldorf:AAJ0 · This pageDusseldorfGermanyEUR
Munich:AAJ0MunichGermanyEUR
Stuttgart:AAJ0StuttgartGermanyEUR
Tradegate:AAJ0TradegateGermanyEUR
Frankfurt:AAJ0FrankfurtGermanyEUR

Valuation

EV/sales −570× against a median of 16.2×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$114.1M USD
P/E
Loss
EV/sales
−570×
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Perspective Therapeutics, Inc. · AMEX:CATXUS$86.05M−US$114.1Mn/a−570×n/a0.3×n/a0.0×1.47
Cumberland Pharmaceuticals Inc. · NASDAQ:CPIXUS$87.57MUS$11.59M1.3×0.5×n/a1.2×273.7%0.1×0.72
Retension Pharmaceuticals, Inc. · NASDAQ:RTSNUS$87.57MUS$78.38Mn/an/an/an/an/an/an/a
Equillium, Inc. · NASDAQ:EQUS$87.26MUS$34.71Mn/an/an/a1.7×n/a0.0×1.31
Upstream Bio, Inc. · NASDAQ:UPBUS$87.15M−US$119.4Mn/a−41.6×n/a0.4×n/a0.0×1.95
Senhwa Biosciences Inc · TPEX:6492US$86.77MUS$67.44Mn/a2,117×n/a4.6×n/a0.0×n/a
Bioceltix SA · GPW:BCXUS$86.38MUS$72.43Mn/an/an/a5.6×n/a0.0×n/a
Pharmosa Biopharm Inc. · TPEX:6875US$86.04MUS$62.27Mn/a38.5×n/a2.1×−658.1%0.1×n/a
Formosa Pharmaceuticals, Inc. · TWSE:6838US$85.43MUS$48.52Mn/a30.4×n/a2.0×−361.4%0.0×n/a
Genome & Co. · KRX:314130US$85.27MUS$37.21Mn/a2.0×n/a1.6×−169.1%0.0×n/a
Anixa Biosciences, Inc. · NASDAQ:ANIXUS$84.82MUS$70.96Mn/an/an/a5.9×n/a0.0×1.45
Median of the othersUS$86.57MUS$55.39M1.3×16.2×2.0×−265.3%0.0×1.38

Forecasts

10 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
9.93 USD · Analysts' mean
EPS, year to Dec 2026
-0.96 · 7 analysts
Revenue, year to Dec 2026
208K · 4 analysts

Team and board

Officers

OfficerRole
Thijs SpoorChief Executive Officer & Member of the Board of Directors
Joel SendekChief Financial Officer
Chris NennoGeneral Counsel and Corporate Secretary
Annie J. ChengVice President, Investor Relations
Belén Carrillo-RivasSenior Vice President, Global Regulatory Affairs
Edwin SagastumeVice President, CMC Isotope Manufacturing
Fran NewarkVice President, Clinical Operations
Harry JeffreysVice President, Quality
Jeff ZhouVice President, Intellectual Property and Innovation
John J. GrantSenior Vice President, Business Development
John KappelhofSenior Vice President, Program & Portfolio Management
Mengshi LiVice President, Pipeline Discovery
Sarah WilleVice President, People & Culture
Shane CobbExecutive Vice President, Operations
Shilpen PatelSenior Vice President, Clinical Development
Amos HedtChief Business Strategy Officer
Bernhard SixtManaging Director, Europe
Jonathan HuntChief Accounting Officer
Markus PuhlmannChief Medical Officer
Paul LyneChief Science Officer

Board

DirectorRole
Lori WoodsChairperson
Frank MorichMember of the Board of Directors
Heidi HensonMember of the Board of Directors
Maya Martinez-DavisMember of the Board of Directors
Robert Froman WilliamsonMember of the Board of Directors
Thijs SpoorChief Executive Officer & Member of the Board of Directors

Events

Next results
Mar 15, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−8.1%
Q2 2026Aug 10, 2026 · After close+6.0%
Q1 2026May 11, 2026 · After close−2.8%
Q4 2025Mar 26, 2026−10.0%
Q3 2025Nov 10, 2025 · After close0.0%
Q2 2025Aug 13, 2025 · Before open−4.3%
Q1 2025May 12, 2025 · After close+1.6%
Q4 2024Mar 26, 2025−6.9%
Q3 2024Nov 12, 2024 · After close−6.9%
Q2 2024Aug 12, 2024 · After close+5.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open−10.8%
Q4 2023Mar 31, 2024 · After close+7.6%
Q3 2023Nov 14, 2023 · After close+8.5%
Q2 2023Aug 11, 2023 · Before open−1.9%
Q1 2023May 15, 2023 · After close−21.5%
Q4 2022Feb 16, 2023 · After close+0.0%
Q3 2022Nov 14, 2022 · After close+6.5%
Q4 2022Sep 28, 2022 · After close−27.4%
Q1 2022May 10, 2022 · After close−8.7%
Q4 2021Feb 8, 2022 · After close+7.0%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings87 slidesNov 9, 2026
NANETS 2026Conference17 slidesNov 6, 2026
NANETS (November 2026)Conference15 slidesNov 6, 2026
ESMO 2026Conference25 slidesOct 23, 2026
Investor Presentation (October 2026)Investor deck87 slidesOct 1, 2026
Investor Presentation (September 2026)Investor deck77 slidesSep 8, 2026
Investor Presentation (July 2026)Investor deck60 slidesJul 1, 2026
Investor Presentation (June 2026)Investor deck56 slidesJun 1, 2026
Investor Day (May 2026)Investor day124 slidesMay 4, 2026
Investor Presentation (April 2026)Investor deck52 slidesApr 20, 2026
All 41 decks
DeckKindSlidesDate
Investor Presentation (April 2026)Investor deck53 slidesApr 1, 2026
FY2025 Earnings PresentationEarnings53 slidesMar 16, 2026
Investor Presentation (February 2026)Investor deck52 slidesFeb 3, 2026
Investor Presentation (January 2026)Investor deck33 slidesJan 14, 2026
Investor Presentation (December 2025)Investor deck68 slidesDec 1, 2025
Investor Presentation (November 2025)Investor deck66 slidesNov 6, 2025
ESMO 2025Conference31 slidesOct 20, 2025
Investor Presentation (October 2025)Investor deck64 slidesOct 1, 2025
Investor Presentation (September 2025)Investor deck63 slidesSep 2, 2025
Investor Presentation (August 2025)Investor deck64 slidesAug 13, 2025
Investor Presentation (July 2025)Investor deck63 slidesJul 3, 2025
Investor Presentation (May 2025)Investor deck26 slidesMay 30, 2025
Investor Presentation (May 2025)Investor deck63 slidesMay 12, 2025
Investor Presentation (March 2025)Investor deck62 slidesMar 26, 2025
Investor Presentation (March 2025)Investor deck51 slidesMar 4, 2025
Investor Presentation (February 2025)Investor deck50 slidesFeb 3, 2025
Investor Presentation (January 2025)Investor deck28 slidesJan 24, 2025
Investor Presentation (January 2025)Investor deck50 slidesJan 13, 2025
Investor Presentation (December 2024)Investor deck112 slidesDec 4, 2024
NANETS 2024Conference35 slidesNov 21, 2024
Investor Presentation (November 2024)Investor deck106 slidesNov 15, 2024
Investor Presentation (August 2024)Investor deck111 slidesAug 13, 2024
Investor Day (March 2024)Investor day100 slidesMar 19, 2024
Investor Presentation (March 2024)Investor deck87 slidesMar 8, 2024
Investor Presentation (February 2024)Investor deck88 slidesFeb 5, 2024
Investor Presentation (January 2024)Investor deck86 slidesJan 17, 2024
Investor Presentation (January 2024)Investor deck73 slidesJan 3, 2024
Investor Presentation (November 2023)Investor deck52 slidesNov 28, 2023
Investor Presentation (September 2023)Investor deck45 slidesSep 5, 2023
Investor Presentation (March 2023)Investor deck41 slidesMar 15, 2023
Isoray — Investor Presentation (December 2019)Investor deck32 slidesDec 10, 2019

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$175M · US$3.79 a share · Piper Sandler +5
Dealers: Piper Sandler (co-lead), UBS Investment Bank (co-lead), Oppenheimer & Co. (co-lead), Truist Securities (co-lead), LifeSci Capital (co-lead), Jones
Buyers: Commodore Capital; TCGX; Spruce Street Capital; Surveyor Capital (a Citadel company); Affinity Asset Advisors; HBM Healthcare Investments; Ally Bridge Group
Use of proceeds: Advance clinical development of product candidates, invest in manufacturing facilities, working capital and general corporate purposes
Feb 2, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Revenue884.0K1.45M1.43M7.10M010.8M10.8M10.1M10.1M9.68M
Cost of revenue3.25M2.31M5.47M3.05M6.18M6.18M4.93M4.93M4.56M
Gross profit-2.37M-852.0K1.43M1.63M004.62M5.12M5.12M5.12M
Research and development84.2M41.6M21.3M2.60M881.0K850.0K2.58M1.43M1.43M1.13M
Selling, general and administrative30.2M26.6M21.0M10.9M9.35M6.62M9.43M4.69M4.69M4.57M
Operating income-113.6M-90.9M-40.9M-15.2M-8.67M-6.42M-7.39M-3.45M-3.44M-3.48M
Depreciation and amortization3.25M2.31M986.0K344.0K267.0K248.0K248.0K149.0K149.0K147.0K
EBITDA-110.3M-88.6M-40.0M-14.8M-8.40M-6.17M-7.14M-3.30M-3.29M-3.33M
Interest expense376.0K48.0K84.0K0050.0K30.0K
Income before tax-104.4M-80.4M-40.1M-14.7M-8.05M-6.30M-7.27M-3.39M-3.39M-3.45M
Income tax-793.0K-2.10M-2.65M000-199.0K0
Net income-103.1M-79.3M-46.5M-14.7M-10.8M-7.27M-7.27M-3.39M-3.19M-3.45M
Earnings per share, basic-1.40-1.23-1.74-0.10-0.08-0.05-0.51-0.03-0.06-0.05
Earnings per share, diluted-1.40-1.23-1.74-0.03-0.05

Balance sheet

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Cash and equivalents30.6M61.6M9.24M21.0M21.0M55.9M55.9M63.8M9.59M2.39M
Short-term investments114.1M165.3M022.8M22.8M0000
Receivables6.00K116.0K1.17M1.36M1.36M1.61M1.61M2.01M1.74M2.04M
Inventory1.41M1.41M1.40M1.40M980.0K665.0K645.0K
Current assets148.4M231.2M16.8M53.2M53.2M59.3M59.3M67.3M12.3M5.51M
Property, plant and equipment76.6M57.3M5.58M371.0K1.98M1.96M1.74M
Goodwill024.1M0
Total assets267.0M341.1M97.9M58.1M58.1M64.4M64.4M70.4M15.5M8.70M
Accounts payable20.5M10.3M6.91M1.54M1.54M966.0K966.0K730.0K494.0K654.0K
Current liabilities28.7M18.2M15.7M2.68M3.12M2.27M2.27M1.80M1.33M1.57M
Long-term debt1.57M1.63M1.68M
Total debt1.63M1.68M1.73M524.0K524.0K776.0K897.0K1.00M
Total liabilities59.9M50.4M22.7M3.45M3.45M3.16M3.16M3.01M2.74M2.98M
Shareholders' equity207.0M290.7M75.2M54.6M54.6M61.3M61.3M67.4M12.8M5.72M
Shares outstanding74.3M70.7M28.2M142.1M142.1M142.0M14.2M141.9M54.9M68.9M

Cash flow

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Cash from operations-82.5M-18.3M-36.9M-12.2M-10.4M-7.71M-7.71M-2.84M-2.84M-3.64M
Capital spending-12.7M-54.4M-1.07M-302.0K-282.0K-266.0K-266.0K-381.0K-381.0K-273.0K
Free cash flow-95.2M-72.7M-38.0M-12.5M-10.7M-7.98M-7.98M-3.22M-3.22M-3.91M
Cash from investing41.2M-218.9M24.4M-29.0M-284.0K-410.0K-410.0K-287.0K
Cash from financing10.3M289.4M785.0K56.0K28.0K56.0K56.0K64.7M64.7M994.0K
Dividends paid00-9.00K-9.00K-11.0K
Change in cash-31.0M52.2M-11.8M182.0K-39.4M-7.94M-7.94M61.4M61.4M-2.93M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
8-K · Current reportNov 6, 2026Current reportSEC
8-K · Current reportNov 6, 2026Current reportSEC
8-K · Current reportOct 23, 2026Current reportSEC
8-K · Current reportOct 8, 2026Current reportSEC
8-K · Current reportOct 1, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 23, 2026Big-stake noticeSEC
8-K · Current reportSep 14, 2026Current reportSEC
8-K · Current reportSep 8, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 4, 2026Big-stake noticeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
8-K · Current reportAug 3, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 20, 2026Big-stake noticeSEC
8-K · Current reportJul 1, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 30, 2026Big-stake noticeSEC
8-K · Current reportJun 1, 2026Current reportSEC
8-K · Current reportMay 27, 2026Meeting outcomeSEC
8-K · Current reportMay 21, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
8-K · Current reportMay 4, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
8-K · Current reportApr 20, 2026Current reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
8-K · Current reportApr 1, 2026Current reportSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 10, 2026Big-stake noticeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2026Big-stake noticeSEC
8-K · Current reportFeb 3, 2026Material contractSEC
424B5 · ProspectusFeb 2, 2026Offer documentSEC
FWP · Free writing prospectusFeb 2, 2026Offer documentSEC
8-K · Current reportFeb 2, 2026ResultsSEC
8-K · Current reportJan 14, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportJan 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 5, 2025Big-stake noticeSEC
8-K · Current reportDec 1, 2025Current reportSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
8-K · Current reportNov 6, 2025Current reportSEC
8-K · Current reportNov 3, 2025Management or board changeSEC
8-K · Current reportOct 20, 2025ResultsSEC
8-K · Current reportOct 1, 2025Current reportSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 5, 2025Insider tradeSEC
8-K · Current reportSep 4, 2025Management or board changeSEC
8-K · Current reportSep 3, 2025Management or board changeSEC
8-K · Current reportSep 2, 2025Current reportSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
8-K · Current reportAug 1, 2025Current reportSEC
8-K · Current reportJul 3, 2025Current reportSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 3, 2025Current reportSEC
8-K · Current reportMay 30, 2025Current reportSEC
8-K · Current reportMay 28, 2025Meeting outcomeSEC
SD · Specialized disclosureMay 19, 2025ESG reportSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
8-K · Current reportMay 1, 2025Current reportSEC
8-K · Current reportApr 29, 2025Current reportSEC
DEFA14A · Additional proxy materialApr 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2025Meeting noticeSEC
8-K · Current reportApr 11, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveApr 9, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 4, 2025Offer documentSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
10-K/A · Annual report, amendedMar 28, 2025Annual reportSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 26, 2025Offer documentSEC
10-K · Annual reportMar 26, 2025Annual reportSEC
8-K · Current reportMar 26, 2025ResultsSEC
POSASRMar 26, 2025Other filingsSEC
8-K · Current reportMar 17, 2025Current reportSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportMar 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 3, 2025Current reportSEC
8-K · Current reportJan 24, 2025Current reportSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2025Insider tradeSEC
8-K · Current reportJan 6, 2025Management or board changeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
4/A · Change in ownership, amendedDec 4, 2024Insider tradeSEC
4/A · Change in ownership, amendedDec 4, 2024Insider tradeSEC
8-K · Current reportDec 3, 2024Current reportSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
8-K · Current reportNov 21, 2024Current reportSEC
8-K · Current reportNov 15, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
8-K · Current reportOct 11, 2024Current reportSEC
8-K · Current reportSep 20, 2024Acquisition or disposalSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
8-K · Current reportSep 5, 2024Current reportSEC
8-K · Current reportAug 30, 2024Management or board changeSEC
8-K · Current reportAug 19, 2024Management or board changeSEC
S-8 · Registration statement for employee plansAug 13, 2024Offer documentSEC
8-K · Current reportAug 13, 2024Material contractSEC
424B5 · ProspectusAug 13, 2024Offer documentSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024Current reportSEC
8-K/A · Current report, amendedAug 12, 2024ResultsSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 24, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Current reportSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4/A · Change in ownership, amendedJun 5, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
8-K · Current reportMay 31, 2024Management or board changeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Material contractSEC
424B5 · ProspectusMay 24, 2024Offer documentSEC
FWP · Free writing prospectusMay 24, 2024Offer documentSEC
S-3ASR · Registration statementMay 24, 2024Offer documentSEC
8-K · Current reportMay 20, 2024Current reportSEC
SD · Specialized disclosureMay 15, 2024ESG reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
4 · Change in ownershipApr 24, 2024Insider tradeSEC
SC 13G · Big-stake noticeApr 19, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 18, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2024Meeting noticeSEC
8-K · Current reportApr 16, 2024Acquisition or disposalSEC
EFFECT · Notice that a registration is effectiveApr 10, 2024Other filingsSEC
424B3 · ProspectusApr 9, 2024Offer documentSEC
CORRESP · Letter to the SECApr 8, 2024Other filingsSEC
PRE 14A · Preliminary proxy statementApr 8, 2024Meeting noticeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Perspective Therapeutics, Inc.’s releases · as of Feb 2, 2026

Common shares
114,151,663
Fully diluted
114,151,663

Fully diluted

LineShares
Common shares114,151,663

Share count over time

CountShares
Nov 22, 2026114,151,663

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock11.8M10.4%US$32.5MSep 30, 2026
TCG Crossover Management, LLC7.92M6.9%US$21.8MSep 30, 2026
Millennium6.19M5.4%US$17MSep 30, 2026
Avidity Partners Management LP6.07M5.3%US$16.7MSep 30, 2026
Vanguard6.03M5.3%US$16.6MSep 30, 2026
Affinity Asset Advisors, LLC3.99M3.5%US$11MSep 30, 2026
Citadel3.98M3.5%US$10.9MSep 30, 2026
Spruce Street Capital LP3.69M3.2%US$10.2MSep 30, 2026
Two Sigma3M2.6%US$8.26MSep 30, 2026
ADAR1 Capital Management, LLC2.62M2.3%US$7.2MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Nantahala Capital Management, LLC2.49M2.2%US$6.85MSep 30, 2026
Geode Capital2.04M1.8%US$5.6MSep 30, 2026
State Street2.03M1.8%US$5.57MSep 30, 2026
Nicholson Wealth Management Group, LLC1.62M1.4%US$4.45MSep 30, 2026
Marshall Wace, LLP1.48M1.3%US$4.08MSep 30, 2026
UBS1.26M1.1%US$3.47MSep 30, 2026
Dimensional1.23M1.1%US$3.37MSep 30, 2026
Yu Fan1.06M0.92%US$2.9MSep 30, 2026
Hills Bank & Trust Co872K0.76%US$2.4MSep 30, 2026
Schwab831K0.73%US$2.29MSep 30, 2026
Northern Trust781K0.68%US$2.15MSep 30, 2026
Goldman Sachs737K0.65%US$2.03MSep 30, 2026
Morgan Stanley624K0.55%US$1.72MSep 30, 2026
Voya Investment Management LLC454K0.40%US$1.25MSep 30, 2026
RBC437K0.38%US$1.2MSep 30, 2026
WealthPlan Investment Management, LLC404K0.35%US$1.11MSep 30, 2026
Bank of America373K0.33%US$1.03MSep 30, 2026
Wellington371K0.32%US$1.02MSep 30, 2026
Nuveen359K0.31%US$988KSep 30, 2026
BNY308K0.27%US$846KSep 30, 2026
Seven Fleet Capital Management LP296K0.26%US$814KSep 30, 2026
Gsa Capital Partners LLP295K0.26%US$812KSep 30, 2026
Fidelity268K0.23%US$737KSep 30, 2026
Federated Hermes, Inc.227K0.20%US$625KSep 30, 2026
Renaissance Technologies222K0.19%US$609KSep 30, 2026
BNP Paribas220K0.19%US$606KSep 30, 2026
Citigroup Inc215K0.19%US$591KSep 30, 2026
XTX Topco Ltd185K0.16%US$510KSep 30, 2026
Ally Bridge Group (NY) LLC164K0.14%US$450KSep 30, 2026
American Century147K0.13%US$405KSep 30, 2026
Rhumbline Advisers135K0.12%US$372KSep 30, 2026
Bridgeway Capital Management, LLC134K0.12%US$368KSep 30, 2026
Barclays127K0.11%US$349KSep 30, 2026
JPMorgan126K0.11%US$331KSep 30, 2026
Empowered Funds, LLC123K0.11%US$338KSep 30, 2026
AllianceBernstein109K0.10%US$301KSep 30, 2026
Trueblood Wealth Management, LLC99,7400.09%US$274KSep 30, 2026
DWS88,1260.08%US$242KSep 30, 2026
Taylor & Morgan Wealth Management, LLC86,0000.08%US$237KSep 30, 2026
T. Rowe Price85,9300.08%US$237KSep 30, 2026

This page holds 50 of 114 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF4.04M3.5%US$13.8MJun 30, 2026
Vanguard Total Stock Market Index Fund3.31M2.9%US$11.3MJun 30, 2026
iShares Russell 2000 ETF2.65M2.3%US$9.03MJun 30, 2026
Fidelity Small Cap Index Fund1.13M0.99%US$3.28MJul 31, 2026
Vanguard Extended Market Index Fund1.02M0.89%US$3.47MJun 30, 2026
iShares Russell 2000 Value ETF978K0.86%US$3.33MJun 30, 2026
iShares Biotechnology ETF636K0.56%US$2.17MJun 30, 2026
Fidelity Extended Market Index Fund446K0.39%US$1.76MMay 31, 2026
Schwab U.S. Small-Cap ETF405K0.35%US$1.6MMay 31, 2026
iShares Micro-Cap ETF347K0.30%US$1.18MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund320K0.28%US$1.26MMay 31, 2026
Vanguard Health Care Index Fund288K0.25%US$1.14MMay 31, 2026
U.S. Small Cap Portfolio270K0.24%US$784KJul 31, 2026
Select Biotechnology Portfolio259K0.23%US$1.02MMay 31, 2026
Dimensional U.S. Small Cap ETF254K0.22%US$740KJul 31, 2026
Schwab Small-Cap Index Fund251K0.22%US$731KJul 31, 2026
U.S. Micro Cap Portfolio237K0.21%US$690KJul 31, 2026
Nuveen Equity Index Fund193K0.17%US$563KJul 31, 2026
Master Small Cap Index Series193K0.17%US$658KJun 30, 2026
Federated Hermes MDT Small Cap Growth Fund189K0.17%US$549KJul 31, 2026
Fidelity Total Market Index Fund169K0.15%US$666KMay 31, 2026
Fidelity Small Cap Value Index Fund145K0.13%US$493KJun 30, 2026
Nuveen Small Cap Blend Index Fund137K0.12%US$400KJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares137K0.12%US$399KJul 31, 2026
Vanguard U.S. Momentum Factor ETF136K0.12%US$537KMay 31, 2026
Fidelity Series Total Market Index Fund129K0.11%US$510KMay 31, 2026
Voya Small Company Portfolio118K0.10%US$402KJun 30, 2026
EQ/2000 Managed Volatility Portfolio112K0.10%US$382KJun 30, 2026
Voya MI Dynamic Small Cap Fund106K0.09%US$417KMay 31, 2026
Dimensional U.S. Core Equity 2 ETF95,8300.08%US$279KJul 31, 2026
Avantis U.S. Small Cap Equity ETF87,7250.08%US$346KMay 31, 2026
LVIP State Street Small-Cap Index Fund75,6000.07%US$258KJun 30, 2026
BlackRock Advantage SMID Cap Fund, Inc.73,3260.06%US$250KJun 30, 2026
Schwab U.S. Broad Market ETF63,5220.06%US$250KMay 31, 2026
EQ/Small Company Index Portfolio61,7800.05%US$211KJun 30, 2026
Vanguard Balanced Index Fund57,9110.05%US$197KJun 30, 2026
Schwab Total Stock Market Index Fund53,4710.05%US$156KJul 31, 2026
Small Cap Index Fund53,4600.05%US$182KJun 30, 2026
EQ/AB Small Cap Growth Portfolio53,0100.05%US$181KJun 30, 2026
Diversified Equity Alpha Master Portfolio52,4050.05%US$179KJun 30, 2026
Ultra-Small Company Market Fund50,0000.04%US$171KJun 30, 2026
Global X Russell 2000 ETF49,3450.04%US$144KJul 31, 2026
U.S. Vector Equity Portfolio48,8750.04%US$142KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund47,7320.04%US$163KJun 30, 2026
Vanguard Russell 2000 Value Index Fund47,6690.04%US$188KMay 31, 2026
Fidelity ZERO Total Market Index Fund44,0850.04%US$128KJul 31, 2026
Biotechnology Ultrasector Profund38,4840.03%US$112KJul 31, 2026
MetLife Russell 2000 Index Portfolio34,7880.03%US$119KJun 30, 2026
Fidelity ZERO Extended Market Index Fund30,5370.03%US$88,863Jul 31, 2026
Small-Cap Index Portfolio29,4500.03%US$100KJun 30, 2026

This page holds 50 of 118 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Lantheus Alpha Therapy, LLC
10% owner
Sale167,149USD 3.15US$527KSep 4, 2026
Lantheus Alpha Therapy, LLC
10% owner
Sale80,783USD 3.11US$251KSep 3, 2026
Lantheus Holdings, Inc.
10% owner
Sale42,129USD 3.11US$131KSep 2, 2026
Lantheus Alpha Therapy, LLC
10% owner
Sale35,769USD 3.12US$112KSep 1, 2026
Lantheus Holdings, Inc.
10% owner
Sale35,769USD 3.12US$112KSep 1, 2026
Lantheus Alpha Therapy, LLC
10% owner
Sale78,145USD 3.14US$245KAug 31, 2026
Lantheus Holdings, Inc.
10% owner
Sale78,145USD 3.14US$245KAug 31, 2026

Big stakes

StakeStakeSharesDateFiling
Chen Yu6.90%7.92MFeb 3, 2026Schedule 13G
BlackRock, Inc.6.80%7.78MJun 30, 2026Schedule 13G
Qatar Investment Authority6.20%7.07MFeb 4, 2026Schedule 13G
Commodore Capital LP5.50%6.6MSep 30, 2026Schedule 13G
Millennium Management LLC5.50%6.32MAug 7, 2026Schedule 13G
Avidity Partners Management LP5.30%6.05MFeb 20, 2026Schedule 13G
Lantheus Holdings, Inc.3.90%4.74MNov 10, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Heidi Henson
Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 15, 2022); PepGen Inc. (Non-Executive Director · Since at least May 5, 2022); Pardes Biosciences Inc (Chief Financial Officer · Dec 23, 2021 – Aug 31, 2023 · Past); Kura Oncology, Inc. (Chief Financial Officer · Mar 6, 2015 – Jan 24, 2018 · Past)
Director · Since at least Jun 1, 2023
Johan M Spoor
Other companies: GridAI Technologies Corp. (Director · Oct 11, 2016 – Apr 6, 2020 · Past); MetaStat Inc (Director · May 22, 2012 – Dec 31, 2014 · Past); FluoroPharma Medical Inc (CEO, PRESIDENT, CHAIRMAN, Director · Nov 18, 2011 – Jan 7, 2014 · Past)
Chief Executive Officer, Director · Since at least Feb 3, 2023
Frank Morich
Other companies: Cue Biopharma, Inc. (Director · Since at least Jul 31, 2018)
Director · Since at least Feb 3, 2023
Joel Sendek
Other companies: Spero Therapeutics, Inc. (Chief Financial Officer · Nov 1, 2017 – Jan 2, 2019 · Past)
Chief Financial Officer · Since at least Sep 4, 2025
Alan HoffmannDirector · Jan 13, 2016 – Jul 21, 2022 · Past
Amos HedtChief Business Strategy Officer · Since at least Nov 4, 2026
Annie J. ChengVice President, Investor Relations · Since at least Oct 23, 2026
Belén Carrillo-RivasSenior Vice President, Global Regulatory Affairs · Since at least Nov 5, 2026
Bernhard SixtManaging Director, Europe · Since at least Nov 5, 2026
Brien RagleCFO · Oct 2, 2009 – Jun 21, 2016 · Past
All 39 people
PersonSeat
Chris NennoGeneral Counsel and Corporate Secretary · Since at least Nov 4, 2026
Dwight William BabcockCEO, Director · Mar 31, 2006 – Nov 12, 2015 · Past
Edwin SagastumeVice President, CMC Isotope Manufacturing · Since at least Nov 5, 2026
Frank MorichMember of the Board of Directors · Since at least Nov 4, 2026
Fran NewarkVice President, Clinical Operations · Since at least Nov 5, 2026
Harry JeffreysVice President, Quality · Since at least Nov 5, 2026
Jeff ZhouVice President, Intellectual Property and Innovation · Since at least Nov 4, 2026
John J. GrantSenior Vice President, Business Development · Since at least Nov 5, 2026
John KappelhofSenior Vice President, Program & Portfolio Management · Since at least Nov 5, 2026
Jonathan HuntChief Accounting Officer · Since at least Nov 13, 2025
Krista ClineDir. of Operations, Secretary · Sep 11, 2018 – Jun 23, 2020 · Past
Lori WoodsChairperson · Since at least Dec 12, 2023
Maria E MartinezDirector · Since at least Sep 3, 2025
Markus PuhlmannChief Medical Officer · Since at least Dec 12, 2023
Matthew BransonPrincipal Fin & Acct Officer · Jan 17, 2017 – Jun 15, 2017 · Past
Maya Martinez-DavisMember of the Board of Directors · Since at least Sep 3, 2025
Mengshi LiVice President, Pipeline Discovery · Since at least Nov 5, 2026
Michael KrachonEVP of Sales & Marketing · Jun 14, 2016 – Oct 22, 2020 · Past
Michael W McCormickDirector · Jun 18, 2019 – Feb 21, 2023 · Past
Paul LyneChief Science Officer · Since at least Nov 5, 2026
Philip J VitaleDirector · Jan 15, 2014 – Jul 21, 2022 · Past
Robert Froman WilliamsonMember of the Board of Directors · Since at least Nov 5, 2026
Robert F Williamson IIIDirector · Since at least Feb 3, 2023
Roger GirardCEO & President, Director · Aug 8, 2006 – Nov 12, 2007 · Past
Sarah WilleVice President, People & Culture · Since at least Nov 5, 2026
Shane CobbExecutive Vice President, Operations · Since at least Nov 5, 2026
Shilpen PatelSenior Vice President, Clinical Development · Since at least Nov 5, 2026
Thijs SpoorChief Executive Officer & Member of the Board of Directors · Since at least Oct 23, 2026
William CavanaghChief R&D Officer · Oct 7, 2010 – Jul 21, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Perspective Therapeutics, Inc.